Agents of Change: Improving the Collaboration Among CAR T Center Experts and Community-Based Clinicians for Improved Care of DLBCL Patients
| Target Professions: | DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director |
| Target Specialties: | Hematology, Hematology/Oncology, Oncology |
| Credits Available: | 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE |
This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.
CME/CE Accreditation Information
Itinerary
Part 1
This assessment will provide a baseline measure of your knowledge of CAR T-cell therapy and management for DLBCL, including, barriers, and challenges for treatment.
Lisocabtagene maraleucel safety and efficacy data
Axicabtagene ciloleucel safety and efficacy data
Lisocabtagene maraleucel safety and efficacy data
Eligibility, logistics, and barriers to early referral for CAR T-cell therapy
Lisocabtagene maraleucel safety and efficacy data
Shared clinician-patient decision-making when considering CAR T-cell therapy
This assessment will provide a measure of knowledge and competence gained from completion of the study modules.
Join your group colleagues to discuss the program curriculum, including a review of the foundational videos. Bring your key questions and discussion points to engage in a robust conversation related to CAR T-cell therapy for DLBCL.
Part 2
This is the story of Mr. R, who will undergo CAR T-cell therapy. Review each section of the case and respond to your challenge assignments.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the early referral and complex management of your patients with DLBCL.
Join your group colleagues to discuss the case scenario, including your management recommendations, and challenges identified.
Interested in becoming a Group Leader?
Group leaders are CAR T-specialized center hematologists or hematologist-oncologists who have extensive experience specifically with CAR T management for patients with DLBCL, and who care for these patients in specialized CAR T centers (and therefore meet REMS criteria). Apply Now
